Tower Research Capital LLC (Trc) Morpho Sys Ag Transaction History

Tower Research Capital LLC (Trc)

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$8.6 - $18.18 $10,242 - $21,652	1,191 New	1,191 $21,000
Q3 2022 Nov 10, 2022	BUY	$4.14 - $22.13 $20 - $110	5 New	5 $0
Q1 2022 May 12, 2022	SELL	$5.87 - $9.73 $2,471 - $4,096	-421 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$9.08 - $12.45 $3,822 - $5,241	421 New	421 $4,000
Q3 2021 Nov 15, 2021	SELL	$11.76 - $19.51 $29,106 - $48,287	-2,475 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$18.95 - $23.95 $46,901 - $59,276	2,475 New	2,475 $48,000
Q1 2021 May 17, 2021	SELL	$21.56 - $30.66 $3,039 - $4,323	-141 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$24.81 - $30.33 $3,498 - $4,276	141 New	141 $4,000
Q3 2020 Nov 16, 2020	SELL	$30.28 - $35.72 $3,058 - $3,607	-101 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$24.08 - $33.35 $2,432 - $3,368	101 New	101 $3,000
Q1 2020 May 15, 2020	SELL	$18.86 - $37.36 $17,860 - $35,379	-947 Closed	0 $0
Q4 2019 Feb 07, 2020	BUY	$26.07 - $36.32 $24,688 - $34,395	947 New	947 $34,000
Q3 2018 Nov 13, 2018	SELL	$26.64 - $35.66 $26,160 - $35,018	-982 Closed	0 $0
Q2 2018 Aug 15, 2018	BUY	$25.15 - $30.6 $24,697 - $30,049	982 New	982 $30,000

1.8M

14.7K

Ticker MOR
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 136,614,000
Description
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.